On June 21, 2022 xCures, Inc., reported their partnership with Novocure with the intent to develop the first comprehensive, longitudinal Quality of Life (QoL) dataset for glioblastoma (GBM) patients (Press release, xCures, JUN 21, 2022, View Source [SID1234616127]). The alliance between both oncology companies will leverage xCures’ novel, patient-centric platform and deep connections to GBM patient and provider communities through direct engagement with GBM patients, unique partnerships with advocacy groups such as the Musella Foundation, and the offering of valuable services such as cancer history structuring and treatment options research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to team up with Novocure and see our extensive real-world data from GBM patients applied towards developing a time series analysis of QOL in GBM," said Mika Newton, CEO of xCures. "As a patient-centric company, we look forward to the outputs of this partnership and to seeing how they improve Quality of Life for those with this devastating cancer."

Participants enrolled in xINFORM are invited weekly to complete the EuroQol 5-Dimension (EQ-5D-5L) QoL survey. The survey results provided by patients will allow for time series analysis of QoL in GBM. Over the coming year, Novocure and xCures will generate QoL data for 250 patients and integrate it with regulatory-compliant longitudinal outcomes data.